The L1CAM gene SPG1 genetic test is a specialized diagnostic procedure designed to identify mutations in the L1 cell adhesion molecule (L1CAM) gene, which are known to cause X-linked hydrocephalus and MASA (mental retardation, aphasia, shuffling gait, and adducted thumbs) syndrome, as well as contribute to the development of spastic paraplegia 1 (SPG1). This test is crucial for individuals showing symptoms of these conditions or for families with a history of related genetic disorders, as early diagnosis can lead to better management and understanding of the condition.
Conducted at DNA Labs UAE, a leading facility in genetic testing and analysis, the L1CAM gene SPG1 genetic test is performed with cutting-edge technology to ensure high accuracy and reliability of results. The test involves collecting a DNA sample, typically through a blood draw or cheek swab, which is then analyzed for specific mutations in the L1CAM gene that are indicative of the aforementioned conditions.
The cost of the L1CAM gene SPG1 genetic test at DNA Labs UAE is set at 4400 AED. This cost reflects the comprehensive nature of the test, including the sophisticated analysis and the expertise required to interpret the results accurately. Individuals considering this test are advised to consult with a genetic counselor or healthcare provider to understand the implications of the results and the next steps in the management or treatment of the condition.
The KIF5A Gene SPG10 Genetic Test is a specialized diagnostic procedure aimed at identifying mutations in the KIF5A gene, which are associated with Spastic Paraplegia 10 (SPG10). SPG10 is a form of hereditary spastic paraplegia, a group of genetic disorders characterized by progressive weakness and spasticity, primarily in the lower limbs. The KIF5A gene plays a critical role in the transport of molecules within neurons, and mutations in this gene can disrupt neuronal function, leading to the symptoms observed in SPG10.
This genetic test involves analyzing the patient's DNA to detect any abnormalities in the KIF5A gene that could lead to SPG10. It is particularly recommended for individuals showing symptoms of hereditary spastic paraplegia or those with a family history of the condition, as it can provide a definitive diagnosis and help guide treatment and management decisions.
The test is available at DNA Labs UAE, a leading facility in genetic diagnostics and research. The cost of the KIF5A Gene SPG10 Genetic Test at DNA Labs UAE is 4400 AED. This price may include the genetic testing procedure, analysis, and a comprehensive report of the findings, although patients are advised to confirm what is included in the cost with the lab directly. The results from this test can be crucial for affected individuals and their families in understanding their condition and planning for the future.
The SPG11 gene is associated with a condition known as spastic paraplegia 11 (SPG11), which is characterized by progressive weakness and stiffness of the legs. This condition is part of a group of genetic disorders known as hereditary spastic paraplegias, which affect the upper motor neurons in the spinal cord, leading to spasticity and paralysis. Mutations in the SPG11 gene disrupt the normal functioning of neurons, particularly in the parts of the brain and spinal cord that control voluntary movements.
To diagnose this condition, a genetic test for the SPG11 gene can be performed. This test involves analyzing the DNA to look for mutations in the SPG11 gene that are known to cause the condition. Genetic testing can help confirm a diagnosis, guide treatment decisions, and inform family planning options for affected individuals and their families.
In the United Arab Emirates, the SPG11 genetic test is available at DNA Labs UAE. The cost of the test is 4400 AED. DNA Labs UAE is equipped with state-of-the-art technology and staffed by professionals with expertise in genetic testing, ensuring accurate and reliable results. This test is particularly valuable for individuals with a family history of hereditary spastic paraplegia or related symptoms, as it can provide a definitive diagnosis and help in the management of the condition.
The RTN2 gene SPG12 genetic test is a specialized diagnostic procedure aimed at identifying mutations in the RTN2 gene, which are linked to spastic paraplegia 12 (SPG12), a rare form of hereditary spastic paraplegia. This condition is characterized by progressive weakness and stiffness of the legs, which can lead to severe mobility issues and other neurological complications. The test involves analyzing the patient's DNA to detect any genetic abnormalities that may be responsible for the condition.
Performed at DNA Labs UAE, a leading facility in genetic testing, the RTN2 gene SPG12 genetic test is conducted with high precision and accuracy, utilizing advanced genomic technologies. The cost of the test is 4400 AED, reflecting the comprehensive nature of the analysis and the expertise required to interpret the results. This test is crucial for individuals with a family history of hereditary spastic paraplegia or those exhibiting symptoms, as it can provide a definitive diagnosis, inform treatment strategies, and offer insights into the risk of passing the condition onto future generations.
The SELENON gene rigid spine muscular dystrophy genetic test is a specialized diagnostic tool designed to detect mutations in the SELENON gene, which are associated with rigid spine muscular dystrophy (RSMD). RSMD is a rare genetic disorder characterized by muscle weakness and stiffness, particularly affecting the spine and leading to difficulties in movement and posture. The test is conducted through a sample of the patient's DNA, usually obtained via a blood draw, and it aims to provide crucial information on the genetic underpinning of the condition.
This genetic test is a critical step in the diagnosis and management of RSMD, enabling healthcare providers to tailor treatment plans to the specific needs of the patient, including physical therapy, respiratory support, and other interventions aimed at improving quality of life. It also offers valuable information for family planning and the assessment of risk in family members.
The test is available at DNA Labs UAE, a leading facility in genetic testing and diagnostics. The cost of the test is 4400 AED, reflecting the specialized nature of the analysis and the comprehensive insights it provides into the patient's genetic profile. DNA Labs UAE employs cutting-edge technology and adheres to stringent quality standards, ensuring accurate and reliable results for patients and their families.
The CAV3 gene rippling muscle disease genetic test is a specialized diagnostic tool offered by DNA Labs UAE, designed to detect mutations in the CAV3 gene, which are associated with the development of rippling muscle disease (RMD). RMD is a rare genetic disorder characterized by muscle stiffness, muscle mounding, and rippling muscle contractions that occur without muscle degeneration. These symptoms are due to mutations in the CAV3 gene, which encodes caveolin-3, a protein crucial for the normal functioning of muscle cells.
The test involves collecting a DNA sample, usually through a blood draw or cheek swab, which is then analyzed in the laboratory to identify any genetic alterations in the CAV3 gene. The accuracy and specificity of this test make it an invaluable tool for confirming a diagnosis of rippling muscle disease, thereby facilitating appropriate management and treatment strategies for affected individuals.
The cost of the CAV3 gene rippling muscle disease genetic test at DNA Labs UAE is 4400 AED. This price reflects the sophisticated technology and expertise required to accurately identify mutations in the CAV3 gene. By opting for this test, patients and healthcare providers can gain critical insights into the genetic underpinnings of rippling muscle disease, enabling targeted interventions and informed decision-making regarding the patient's health management.
The "SRPX2 Gene Rolandic Epilepsy Mental Retardation and Speech Dyspraxia Genetic Test" is a specialized diagnostic examination offered by DNA Labs UAE, designed to detect mutations in the SRPX2 gene. This gene has been associated with Rolandic epilepsy, a common form of childhood epilepsy that can interfere with speech and cognitive development. Additionally, mutations in the SRPX2 gene have been linked to mental retardation and speech dyspraxia, a speech disorder that affects a person's ability to correctly pronounce words and sounds. The test, priced at 4400 AED, provides crucial genetic information that can guide treatment options, support early intervention strategies, and help families understand the risk of these conditions being passed on to future generations. Conducted in the state-of-the-art facilities of DNA Labs UAE, this genetic test is a vital tool for families seeking answers to complex neurological and developmental conditions.
The PMP22 Gene Roussy-Levy Syndrome Genetic Test is a specialized diagnostic assessment designed to detect mutations in the PMP22 gene, which are associated with Roussy-Levy Syndrome (RLS). This hereditary condition is characterized by a spectrum of symptoms, including muscle weakness, sensory disturbances, and a decreased ability to coordinate movements, leading to significant challenges in daily activities. The test is a crucial tool for confirming the diagnosis, understanding the condition's progression, and guiding treatment decisions.
Conducted at DNA Labs UAE, a leading facility in genetic diagnostics, the test involves collecting a DNA sample, typically through a blood draw or cheek swab, and analyzing it for specific genetic alterations in the PMP22 gene. This gene plays a critical role in the development and function of peripheral nerves, and mutations can lead to the symptoms observed in Roussy-Levy Syndrome.
The cost of the PMP22 Gene Roussy-Levy Syndrome Genetic Test at DNA Labs UAE is 4400 AED. This price reflects the comprehensive nature of the test, including the advanced technology and expertise required to accurately identify mutations in the PMP22 gene. While the cost may seem significant, the insights provided by the test can be invaluable for affected individuals and their families, offering a clearer understanding of the condition and enabling more effective management strategies.
The RUBCN Gene Salih Ataxia Genetic Test is a specialized diagnostic tool designed to detect mutations in the RUBCN gene, which are implicated in the development of Salih Ataxia, a rare neurodegenerative disorder. This condition is characterized by a progressive loss of coordination and movement, leading to significant physical disability over time. The test is particularly relevant for individuals exhibiting symptoms of ataxia, those with a family history of the condition, or couples considering pregnancy and wishing to assess their risk of passing the condition onto their offspring.
Conducted at DNA Labs UAE, a leading facility in genetic testing and analysis, the test involves collecting a DNA sample from the patient, typically through a blood draw or a cheek swab. The sample is then analyzed using advanced genetic sequencing technologies to identify any mutations in the RUBCN gene that are known to cause Salih Ataxia.
The cost of the RUBCN Gene Salih Ataxia Genetic Test is 4400 AED, reflecting the sophisticated technology and expert analysis involved in its execution. Despite the price, for many patients and families, the test provides invaluable insights into their genetic health, guiding treatment decisions, and offering a clearer understanding of their condition's progression and inheritance pattern.
The MYH7 gene plays a critical role in the body's muscle function, particularly in the heart and skeletal muscles. Mutations in the MYH7 gene can lead to various myopathies, including Scapuloperoneal Myopathy, a rare genetic disorder characterized by progressive weakness and atrophy of the muscles in the shoulders (scapula) and legs (peroneal muscles). This condition can significantly impact an individual's quality of life, making early and accurate diagnosis crucial for managing symptoms and planning treatment strategies.
To diagnose this condition, DNA Labs UAE offers a specialized genetic test that focuses on identifying mutations in the MYH7 gene related to Scapuloperoneal Myopathy. This test is a valuable tool for clinicians and genetic counselors in diagnosing patients with symptoms suggestive of MYH7-related conditions, allowing for a more targeted approach to treatment and management.
The cost of the MYH7-related genetic test at DNA Labs UAE is 4400 AED. The testing process involves collecting a DNA sample, typically through a blood draw or cheek swab, which is then analyzed in the lab for specific genetic mutations associated with the MYH7 gene. Results from this test can provide crucial information for affected individuals and their families, including the confirmation of a diagnosis, insights into the progression of the disease, and implications for other family members who may be at risk.
Given the specialized nature of this test and its importance in the diagnosis and management of Scapuloperoneal Myopathy, the investment in testing can be a critical step towards achieving a better understanding of the condition and improving patient care.
